top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance


22/06/2026








Exelixis’ STELLAR-303 trial showed OS benefit in ITT, non‑significant trend in NLM in mCRC; FDA decision due Dec 2026 (Ref)


Exelixis released final analysis results for the NLM (non-liver metastases) subgroup in the Phase 3 STELLAR-303 trial, showing a non-statistically significant OS trend favoring zanzalintinib + atezolizumab vs regorafenib (HR 0.83; median OS 15.9 vs 12.7 months) in previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)


FDA accepted NDA (Feb 2026) for zanzalintinib + atezolizumab in previously treated mCRC patients (fluoropyrimidine, oxaliplatin, irinotecan ± anti-EGFR if RAS wild-type)


  • PDUFA target action date: December 3, 2026













SystImmune secures world’s first bispecific ADC approval with iza-bren in China (Ref)


SystImmune’s parent company, Biokin, received approval from China’s NMPA for iza-bren (BL-B01D1), a first-in-class EGFR×HER3 bispecific ADC, for recurrent/metastatic nasopharyngeal carcinoma (NPC) patients who progressed after platinum chemotherapy and PD-1/PD-L1 therapy


The approval is based on results from the pivotal Phase 3 BL-B01D1-303/NCT06118333 study


  • ORR: 54.6% with iza-bren vs. 27.0% with chemotherapy (OR 3.3; p<0.0001)


  • DoR: 8.5 months vs. 4.8 months


  • PFS: 8.38 months vs. 4.34 months (HR 0.44)


  • OS: Data immature at analysis













CARsgen secures NMPA approval for satri-cel, the world’s first CAR-T therapy in solid tumors, targeting Claudin18.2-positive advanced gastric cancer (Ref)


China’s NMPA approved CARsgen Therapeutics' satri-cel (satricabtagene autoleucel), the world’s first CAR T-cell therapy for solid tumors, specifically Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after ≥2 prior lines of therapy

Clinical Evidence:


  • In confirmatory randomized Ph1/2 CT041-ST-01 trial Satri-cel treatment resulted in a significant improvement in progression-free survival vs treatment of physician's choice (TPC) - Medina PFS: 3.25 mos vs 1.77 mos (HR: 0.37; p<0·0001) (Ref)













Sigvotatug vedotin in metastatic non-squamous NSCLC missed OS in the overall population but showed promising efficacy in second-line patients (Ref)


Pfizer's Phase 3 SigVie-002 study evaluating sigvotatug vedotin (IB6-directed ADC), did not meet its primary endpoint of overall survival (OS) vs docetaxel in previously treated metastatic non-squamous NSCLC. However, the safety profile remained manageable and consistent with prior studies, and the drug showed a promising trend in second-line patients


  • In patients who received only one prior line of therapy (~two-thirds of the 703-patient study), a stronger trend was observed for both OS and progression-free survival (PFS) favoring sigvotatug vedotin over docetaxel


  • In the exploratory analysis, no clear IB6 expression-response relationship was observed













IMUNON's Phase 3 OVATION 3 trial gets green light from Independent Safety Committee for continuation without modification (Ref)


The independent Data Monitoring Committee (iDMC) has recommended the Phase 3 OVATION 3 clinical trial evaluating IMNN-001 continue without any changes, reinforcing confidence in the drug's safety and efficacy profile. With 27 patients currently enrolled, the trial is ahead of schedule and remains on track to reach the 80-patient milestone by end of Q1 2027


  • The committee's recommendation to continue without modification validates the benefit/risk profile established across two prior randomized, controlled trials (OVATION 1 & 2)


  • OVATION 2 showed a median 14.7 mos improvement in overall survival (45.1 vs. 30.4 mos) for IMNN-001 + SoC vs SoC alone; patients also on PARP inhibitors saw a 24.2 mos OS advantage


  • IMNN-001 continues to demonstrate an unprecedented IL-12 safety profile, distinguishing it from conventional immunotherapies


  • Trial Design: The Phase 3 study will enroll 500 patients (1:1 randomization), with overall survival as the primary endpoint, plus secondary endpoints including objective response rate and surgical response score


  • Two Interim Analyses Planned: These could serve as early registration opportunities and accelerate a potential Biologics License Application (BLA) submission to the FDA if statistical significance is reached ahead of full enrollment


Upcoming Milestones:


  • Q1 2027: Target enrollment of ~80 patients


  • Full Enrollment: 500 patients across multiple US sites


  • Interim Analyses: Two scheduled efficacy reviews that could unlock early FDA BLA submission



Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page